RecruitingPhase 4NCT06353529

Postop Pain Management in Pituitary Tumour Patients

Effect of Sphenopalatine Ganglion Block With Bupivacaine on Postoperative Pain in Patients Undergoing Endoscopic Pituitary Adenoma Resection


Sponsor

Hamilton Health Sciences Corporation

Enrollment

108 participants

Start Date

Nov 25, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study looks at pain management after surgery to remove a pituitary tumor through the nose (endonasal approach). Researchers want to find out whether a nerve-blocking technique can help reduce pain and the need for strong pain medications after this type of brain surgery. **You may be eligible if...** - You are 18 years or older - You are scheduled to have a pituitary adenoma removed through your nose (endonasal surgery) **You may NOT be eligible if...** - You already take antidepressants (SSRIs), benzodiazepines, gabapentin, or opioids for a chronic pain condition - You have a known allergy to the medications used in the nerve block - You have chronic alcohol abuse, severe high blood pressure, serious kidney or liver disease, or certain heart conditions (like irregular heart rhythms or cardiomyopathy) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution

2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block

DRUGPlacebo

2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block

DRUGSham Comparator

Participants receive no additional study injections


Locations(1)

Hamilton General Hospital

Hamilton, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06353529


Related Trials